Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Corre

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 StudyRomain Corre, Laurent Greillier, Hervé Le Caër, et al.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
JAMA Oncology|July 17, 2015
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC TrialNiki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 StudyRomain Corre, Laurent Greillier, Hervé Le Caër, et al.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
JAMA Oncology|July 17, 2015
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC TrialNiki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
Pageof 6